Short Interest in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Declines By 64.0%

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) saw a large decrease in short interest in the month of February. As of February 13th, there was short interest totaling 81,117 shares, a decrease of 64.0% from the January 29th total of 225,242 shares. Approximately 0.6% of the company’s shares are short sold. Based on an average daily volume of 182,528 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily volume of 182,528 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.6% of the company’s shares are short sold.

Genenta Science Price Performance

Shares of GNTA stock opened at $1.00 on Thursday. Genenta Science has a 12-month low of $0.71 and a 12-month high of $10.00. The firm has a fifty day moving average of $1.21 and a 200-day moving average of $2.27.

Genenta Science (NASDAQ:GNTA) last announced its earnings results on Friday, October 10th. The company reported ($0.10) earnings per share for the quarter. Research analysts anticipate that Genenta Science will post -0.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genenta Science in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. SmartHarvest Portfolios LLC bought a new stake in Genenta Science in the 4th quarter valued at approximately $26,000. Citadel Advisors LLC acquired a new stake in shares of Genenta Science in the third quarter valued at approximately $41,000. Alyeska Investment Group L.P. bought a new stake in shares of Genenta Science in the fourth quarter worth $328,000. Norges Bank acquired a new position in Genenta Science during the fourth quarter worth $337,000. Finally, Weiss Asset Management LP bought a new position in Genenta Science in the fourth quarter valued at $480,000. 15.13% of the stock is currently owned by institutional investors.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.